M&As this week: NantCell, Shanghai No1 Pharmacy


NantCell has signed a definitive agreement to acquire Altor BioScience for a purchase consideration of approximately $290m.

The deal includes an upfront payment of $2m payable in cash and/or NantCell common stock.

"The deal includes an upfront payment of $2m payable in cash or NantCell common stock."

Bailian Group has acquired approximately 23.4% stake comprising 52,185,126 A shares of Shanghai No1 Pharmacy.

The acquirer is an operator of departmental stores and shopping malls in China, while the target company operates a pharmacy chain in the same country.